Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Canaccord Genuity Downgrades Maxar Technologies to Hold

Canaccord Genuity Downgrades Maxar Technologies to Hold

Canaccord Genuity analyst Austin Moeller downgrades Maxar Technologies (NYSE:MAXR) from Buy to Hold.

byBenzinga Newsdesk

December 16, 2022

1 minute read

Canaccord Genuity analyst Austin Moeller downgrades Maxar Technologies (NYSE:MAXR) from Buy to Hold.

Dynatrace Gets Price Target Hikes By Analysts After Upbeat Results

By Lisa Levin

May 18, 7:33 AM

Dynatrace, Inc (NYSE: DT) reported better-than-expected fourth-quarter results and issued revenue guidance above estimates.

News

Ares Management Raises $3.7B Of Sports, Media And Entertainment Capital

By Benzinga Newsdesk

September 15, 6:31 AM

Inaugural Ares Sports, Media and Entertainment Fund is Over 25% Committed to Date Significant Debt and Equity Investments Include Atlético de Madrid, the San Diego Padres, McLaren Racing and Inter Miami

ARES

Morgan Stanley Maintains Underweight on JPMorgan Chase, Lowers Price Target to $126

By Benzinga Newsdesk

October 5, 7:53 AM

Morgan Stanley analyst Betsy Graseck maintains JPMorgan Chase (NYSE:JPM) with a Underweight and lowers the price target from $127 to $126.

JPM

Health Care Company Merck & Co Announces Acquisition of Harpoon Therapeutics

By Benzinga Insights

January 8, 11:10 AM

Merck & Co (NYSE:MRK) has announced an acquisition of Harpoon Therapeutics (NASDAQ:HARP) that is expected to be completed…

HARP

Canaccord Genuity Downgrades Maxar Technologies to Hold

Related Posts

Dynatrace Gets Price Target Hikes By Analysts After Upbeat Results

Ares Management Raises $3.7B Of Sports, Media And Entertainment Capital

Morgan Stanley Maintains Underweight on JPMorgan Chase, Lowers Price Target to $126

Health Care Company Merck & Co Announces Acquisition of Harpoon Therapeutics